Billiontoone Inc Dossier
Qualitative Analysis
Business overview
BillionToOne, Inc. (NASDAQ: BLLN) is a next-generation molecular diagnostics company specializing in ultra-sensitive genetic testing. The company's proprietary Quantitative Counting Templates (QCT) molecular counting platform enables the detection and precise quantification of DNA molecules at single base-pair resolution. BillionToOne operates primarily in two high-growth clinical segments: prenatal screening and oncology diagnostics. Its flagship prenatal product, the UNITY Fetal Risk Screen, is a non-invasive prenatal test (NIPT) that assesses fetal risk for both chromosomal aneuploidies and common recessively inherited conditions (such as cystic fibrosis, spinal muscular atrophy, and sickle cell disease) directly from maternal cell-free DNA without requiring paternal blood samples. In oncology, the company offers the Northstar Select and Northstar Response liquid biopsy assays, which provide ultra-sensitive therapy selection and real-time treatment response monitoring for late-stage cancer patients.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the adoption of the Northstar Select® and Northstar Response® liquid biopsy tests to target the multi-billion dollar minimal residual disease (MRD) and therapy monitoring markets.
Expected impact: Oncology clinical testing revenue grew to $10.7 million in Q1 2026 (up 392% year-over-year), establishing a major secondary growth engine alongside the core prenatal business.
Developing and launching Unity Confirm™, the first non-invasive prenatal confirmation test that isolates intact circulating fetal cells from maternal blood to perform whole genome sequencing.
Expected impact: Provides a safe, non-invasive alternative to amniocentesis and CVS, capturing a larger share of the high-risk prenatal diagnostic market.
Establishing and scaling a new 220,000-square-foot molecular diagnostics testing facility in Austin, Texas, to handle the surge in demand for NIPT and liquid biopsy services.
Expected impact: Significantly increases sequencing capacity, reduces per-test processing costs, and supports long-term margin expansion.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Integrates BillionToOne's prenatal and oncology testing portfolio (including UNITY Complete®, Northstar Select®, and Northstar Response®) directly into Epic's Aura diagnostics suite, enabling seamless ordering and discrete results delivery for clinicians nationwide.
Terms: Terms of the December 2025 agreement were not publicly disclosed.